Pfizer, Medtronic, Hinge Health offer AI healthcare exposure

The article frames artificial intelligence in healthcare as a structural long-term investment theme distinct from short-term macro headlines, appealing to investors seeking exposure to cost pressures and productivity improvement across healthcare systems. The three stocks spotlighted represent different entry points: Pfizer, a US$142.5b market-cap pharmaceutical giant with about US$61.9b in annual revenue, is positioned as inexpensive relative to peers and offers AI-powered R&D partnerships alongside traditional vaccine and oncology portfolios. Medtronic, valued at US$105.0b with US$36.4b in annual revenue, brings AI surgical tools and robotics (Hugo system) to an established base of cardiovascular and neuromodulation devices. Hinge Health, the smallest at US$5.9b market cap and US$646.3m in revenue, represents a pure-play software and AI approach to digital musculoskeletal care.

Each company carries distinct execution risks that complicate the narrative. Pfizer's dividend sustainability is uncertain given cash flow constraints, while its AI pipeline involves multiple moving parts—oncology, hemophilia, and obesity treatments—rather than a simple growth story. Medtronic faces margin pressure, underperforming diabetes and surgical units, and complexity around a planned diabetes spin-off, raising questions about whether AI initiatives mask deeper operational challenges. Hinge Health, despite analyst guidance raises and index inclusions, still prices in a premium and has a history of losses; the key question for investors is whether its shift toward a software-based model and expansion into new programs already reflects the risks that could alter its growth trajectory.

The article positions these three as starting points within a broader screener of 36 additional companies, emphasizing that the evaluation requires looking beyond headline revenue figures and standard valuation multiples to uncover the hidden catalysts and risks specific to each company's AI healthcare bet.